Physician profile
David A Lee
NPI 1427263441
$2,760.83
in general payments reported to CMS, 2019-2025
31 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $491 · 2021: $489 · 2022: $338 · 2023: $356 · 2024: $340 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $231.68 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $207.31 | 2022-2025 | |
| Pfizer INC. | $206.17 | 2019-2023 | |
| Genzyme Corporation | $205.09 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $198.89 | 2019-2023 | |
| Galderma Laboratories, L.P. | $190.74 | 2019-2021 | |
| Leo Pharma INC. | $144.06 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $142.67 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.90 | 2019-2023 | Arazlo |
| Janssen Biotech, INC. | $112.90 | 2021-2024 | Tremfya, Simponi Aria, Stelara |
| Gilead Sciences, INC. | $97.49 | 2022 | |
| Almirall LLC | $91.88 | 2019-2021 | |
| Amgen INC. | $84.40 | 2020-2023 | Otezla |
| Celgene Corporation | $70.28 | 2019 | |
| Organon LLC | $51.42 | 2025 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.63 | 2020-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $49.52 | 2023-2025 | Sotyktu |
| Strata Skin Sciences, INC. | $47.65 | 2019-2020 | |
| Dermavant Sciences, INC. | $47.29 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $47.24 | 2020-2021 | |
| Sebela Pharmaceuticals INC. | $43.95 | 2020-2022 | |
| Dermira, INC. | $41.07 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $40.23 | 2023 | |
| Kerecis Limited | $39.97 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Epi Health, LLC | $39.67 | 2019 | |
| Ucb, INC. | $38.05 | 2021-2022 | |
| Merz North America, INC. | $28.79 | 2025 | |
| Promius Pharma LLC | $28.74 | 2019 | |
| Mayne Pharma Commercial LLC | $23.38 | 2019 | |
| Allergan, INC. | $17.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.38 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.